Table 7 Menopause status distribution of the patients from which the various samples were obtained
From: Pan-cancer analysis of TCGA data reveals notable signaling pathways
Cancer | Tumor samples | Non-tumor samples | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Pre | Peri | Post | NA | Pre | Peri | Post | NA |
Breast cancer | 104 | 16 | 297 | 49 | 19 | 2 | 28 | 12 |
Colon adenocarcinoma | 0 | 0 | 0 | 143 | 0 | 0 | 0 | 19 |
Glioblastoma | 0 | 0 | 0 | 567 | 0 | 0 | 0 | 10 |
Kidney renal papillary cell carcinoma | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 |
Low grade glioma | 0 | 0 | 0 | 27 | 0 | 0 | 0 | 0 |
Lung adenocarcinoma | 0 | 0 | 0 | 32 | 0 | 0 | 0 | 0 |
Lung squamous cell carcinoma | 0 | 0 | 0 | 154 | 0 | 0 | 0 | 0 |
Ovarian carcinoma | 0 | 0 | 0 | 572 | 0 | 0 | 0 | 8 |
Rectum adenocarcinoma | 0 | 0 | 0 | 69 | 0 | 0 | 0 | 3 |
Uterine corpus endometriod carcinoma | 5 | 0 | 45 | 4 | 0 | 0 | 0 | 0 |
Pan cancer (total) | 109 | 16 | 342 | 1633 | 19 | 2 | 28 | 52 |